BioPorto A/S appoints new Chief Executive Officer and announces changes to the Board of Directors
October 20 2021 - 01:16AM
BioPorto A/S appoints new Chief Executive Officer and announces
changes to the Board of Directors
October 20,
2021Announcement
no. 16
BioPorto A/S appoints new Chief Executive Officer and
announces changes to the Board of Directors
BioPorto A/S (“BioPorto”) has announced the
appointment of Anthony Pare as its new Chief Executive Officer
(CEO). Anthony (Tony) Pare, a US citizen, will join BioPorto
directly from T2 Biosystems, a US Nasdaq-listed in vitro
diagnostics company, where he served as the Chief Commercial
Officer and presided over several successful product launches. He
will start in BioPorto by mid-November 2021.
Prior to T2 Biosystems, Anthony Pare served as
Chief Commercial Officer at Hemanext (US), and in various
commercial and business development leadership roles at Haemonetics
(US), which specialized in blood processing and diagnostic
technologies. He holds a Master’s degree in Engineering
Administration from George Washington University (US).
“I am extremely pleased with the appointment of
Tony as BioPorto’s new CEO. For 24 years, he has been leading
product development, commercialization, marketing and operations
improvements in leading medtech and diagnostic companies. During
this time, he has delivered impressive results, driving business
value, increasing product presence and growing sales, both in the
US and globally. His is a very strong match with BioPorto’s
commercialization plan for The NGAL Test™ and gRAD platform-based
products,” said Christopher Lindop, Vice Chairman of the Board of
Directors at BioPorto.
“I am very excited to take on the role of CEO of
BioPorto from Peter Mørch Eriksen. BioPorto’s superior technologies
have tremendous potential to fundamentally improve diagnosis and
prognosis to benefit patients, physicians and healthcare systems. I
look forward to leading BioPorto as our US and Denmark-based team
works to realize the full value of the company’s pipeline,” Anthony
Pare said.
Changes to the board of directors
As previously announced, outgoing CEO Peter
Mørch Eriksen will remain at BioPorto in a full-time advisory role
until January 2022. Furthermore, the Board of Directors and key
shareholders have asked and Peter Mørch Eriksen has accepted to
stand for election to the Board of Directors. BioPorto will convene
an Extraordinary General Meeting (EGM) for this purpose.
In parallel, after eight years of service,
Chairman of the Board of Directors Thomas Magnussen has decided to
tender his resignation as of the date of the EGM. Christopher
Lindop, who joined BioPorto’s Board in 2019, will succeed Thomas
Magnussen as Chairman.
“I want to thank Thomas for his long-time
dedication to BioPorto. Together with Peter, he has been
instrumental in establishing the strong basis on which BioPorto
stands today – strategically, financially and operationally. At the
same time, I am very pleased Peter has agreed to take on a new
position as member of the Board of Directors. His unique experience
and knowledge will be a valuable addition to the Board as we work
with management to realize BioPorto’s great potential,” said
Christopher Lindop, Vice Chairman of the Board of Directors.
For further information, please contact:
Christopher Lindop, Vice Chairman of the Board of Directors,
BioPorto A/STelephone +1 617 276 2357
Tim Eriksen, Investor Relations, BioPorto A/STelephone: +45 6168
7779Telephone +45 4529 0000, Email investor@bioporto.com
About BioPortoBioPorto is an in vitro
diagnostics company that provides tests and antibodies to
clinicians and researchers around the world. We use our antibody
and assay expertise to transform novel research tools into
clinically actionable biomarkers that can make a difference in
patients’ lives. BioPorto is headquartered in Hellerup, Denmark and
is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].
- 2021 10 20 - Announcement no. 16
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Mar 2023 to Mar 2024